anselamimab + cyclophosphamide + bortezomib + dexamethasone + daratumumab

A combination regimen consisting of **anselamimab**, **cyclophosphamide**, **bortezomib**, **dexamethasone**, and **daratumumab**, primarily investigated for the treatment of **systemic light chain (AL) amyloidosis** and possibly multiple myeloma. This combination incorporates: - **Anselamimab** (an anti-light chain monoclonal antibody, currently investigational) - **Cyclophosphamide** (an alkylating agent causing DNA crosslinking, leading to cell death; used as immunosuppressant and anti-cancer therapy) - **Bortezomib** (a proteasome inhibitor disrupting degradation of proteins, leading to apoptosis of malignant cells) - **Dexamethasone** (a synthetic corticosteroid suppressing inflammation and immune responses) - **Daratumumab** (a monoclonal antibody targeting CD38 on plasma cells, depleting malignant plasma cells via immune-mediated mechanisms[7][5]) This multi-agent regimen is designed for rapid and potent reduction in pathogenic plasma cell burden and toxic light chain production, leveraging complementary mechanisms of action. Daratumumab in particular has received FDA approval as part of various combinations, including with cyclophosphamide, bortezomib, and dexamethasone (CyBorD) for AL amyloidosis[5][7]. Anselamimab is currently in clinical development and is not yet approved. The combination may offer enhanced hematologic responses compared to standard regimens.